Zobrazeno 1 - 10
of 1 990
pro vyhledávání: '"Elder, MJ"'
Autor:
Elder MJ; Pharmacy Innovations and Partnerships, 21614Michigan Medicine, Ann Arbor, MI, USA., Ashjian EJ; Department of Clinical Pharmacy, 15514University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Publikováno v:
Journal of pharmacy practice [J Pharm Pract] 2023 Apr; Vol. 36 (2), pp. 418-428. Date of Electronic Publication: 2021 Oct 07.
Autor:
Matas-Céspedes A; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Lapointe JM; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Elder MJ; Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., Browne GJ; Antibody Discovery and Protein Engineering, R&D , AstraZeneca, Cambridge, United Kingdom., Dovedi SJ; Early Oncology, R&D, AstraZeneca, Cambridge, United Kingdom., de Haan L; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Maguire S; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Stebbings R; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Frontiers in immunology [Front Immunol] 2023 Mar 03; Vol. 14, pp. 1107848. Date of Electronic Publication: 2023 Mar 03 (Print Publication: 2023).
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Dectin-1/CLEC7A is a pattern recognition receptor that recognizes β-1,3 glucans, and its stimulation initiates signaling events characterized by the production of inflammatory cytokines from human dendritic cells (DCs) required for antifungal immuni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f572777e2003478fe94384cbddc3b4ec
Autor:
Webster, SJ, Brode, S, Ellis, L, Fitzmaurice, TJ, Elder, MJ, Gekara, NO, Tourlomousis, P, Bryant, C, Clare, S, Chee, R, Gaston, HJS, Goodall, JC
Publikováno v:
PLoS Pathogens, Vol 13, Iss 6, p e1006383 (2017)
The innate immune system is a critical component of host defence against microbial pathogens, but effective responses require an ability to distinguish between infectious and noninfectious insult to prevent inappropriate inflammation. Using the impor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0bdb63dcd22969c3aaefc5dcc9d657eb
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-137812
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-137812
Autor:
Dovedi SJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com., Elder MJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Yang C; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Sitnikova SI; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Irving L; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Hansen A; Translational Science and Experimental Medicine, Respiratory and Immunology (RI), Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland., Hair J; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jones DC; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hasani S; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Wang B; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Im SA; Division of Hematology-Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University School of Medicine, Seoul, Korea., Tran B; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Subramaniam DS; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gainer SD; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Vashisht K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lewis A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jin X; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Kentner S; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mulgrew K; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wang Y; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Overstreet MG; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Dodgson J; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Wu Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Palazon A; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Morrow M; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Rainey GJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Browne GJ; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Neal F; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Murray TV; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Toloczko AD; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Dall'Acqua W; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland., Achour I; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Freeman DJ; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Wilkinson RW; Early Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mazor Y; Antibody Discovery and Protein Engineering, R&D, AstraZeneca, Gaithersburg, Maryland. simon.dovedi@astrazeneca.com yariv.mazor@astrazeneca.com.
Publikováno v:
Cancer discovery [Cancer Discov] 2021 May; Vol. 11 (5), pp. 1100-1117. Date of Electronic Publication: 2021 Jan 08.
Autor:
Lee, Jung Min1 (AUTHOR), Choi, Se Hyun2 (AUTHOR), Jeon, Gang Seok3 (AUTHOR), Chang, In Boem4 (AUTHOR), Wang, Soon Joo5 (AUTHOR), Hong, In Hwan1,6,7 (AUTHOR) loperter@hanmail.net
Publikováno v:
Scientific Reports. 10/10/2024, Vol. 14 Issue 1, p1-8. 8p.
Autor:
Sung-Ae Cho1 whtjddo89@gmail.com
Publikováno v:
Anesthesia & Pain Medicine. 2024 Supplement, Vol. 19, pS5-S11. 7p.
Autor:
Burke S; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK. shannon.burke@astrazeneca.com., Shergold A; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK., Elder MJ; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK., Whitworth J; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK., Cheng X; BioPharmaceuticals R&D, Clinical Pharmacology & Safety Sciences, AstraZeneca, South San Francisco, CA, USA.; Meissa Vaccines, JLABS, 329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA., Jin H; BioPharmaceuticals R&D, Clinical Pharmacology & Safety Sciences, AstraZeneca, South San Francisco, CA, USA., Wilkinson RW; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK., Harper J; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK., Carroll DK; Oncology R&D, AstraZeneca, Aaron Klug Building, Granta Park, Cambridge, CB21 6GH, UK.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Jun; Vol. 69 (6), pp. 1015-1027. Date of Electronic Publication: 2020 Feb 22.
Autor:
Wang LA; From the College of Medicine., Lai CC; From the College of Medicine.; Department of Ophthalmology, National Cheng Kung University Hospital.; Institute of Clinical Medicine, National Cheng Kung University.
Publikováno v:
Plastic and reconstructive surgery [Plast Reconstr Surg] 2024 Oct 01; Vol. 154 (4), pp. 781e-794e. Date of Electronic Publication: 2023 Oct 03.